In the current study, breast cancer patients underwent various therapies with a single regimen, including chemotherapy (n = 29), hormone therapy (n = 11), and HER2-targeted therapy (n = 2), or with a combination regimen, including hormone plus BPs therapy (n = 26), chemotherapy plus BPs therapy (n = 13), chemotherapy plus HER2-targeted therapy (n = 10), and chemotherapy plus HER2-targeted and BPs therapy (n = 9). The gene discussed is ERBB2; the disease is breast cancer.